Table 4 Possible treatments for adult ALL patients by Ph-positivity, age, and MRD-positivity
Ph | Age (years) | Induction therapy | MRD | Allo HSCT |
|---|---|---|---|---|
− | <45 | Pediatric-inspired Chemotherapy | + | Allo HSCT with medium-dose ETP + CY + TBI in CR1/2 (Haplo HSCT with MAC in the case of lacking an HLA-matched donor in CR1) |
No HSCT | ||||
45–50 | Conventional chemotherapy | Allo HSCT with medium-dose ETP + CY + TBI in CR1/2 (Haplo HSCT with MAC in the case of lacking an HLA-matched donor in CR1) | ||
≧50 | Conventional chemotherapy | − | Allo HSCT with RIC in CR1 (Haplo HSCT with RIC in the case of lacking an HLA- matched donor in CR1) | |
+ | <45 | Conventional or pediatric-inspired chemotherapy + TKI | Allo HSCT with medium-dose ETP + CY + TBI in CR1 (Haplo HSCT with MAC in the case of lacking an HLA-matched donor in CR1) | |
45–50 | Conventional chemotherapy + TKI | Allo HSCT with medium-dose ETP + CY + TBI in CR1/2 (Haplo HSCT with MAC in the case of lacking an HLA-matched donor in CR1) | ||
≧50 | Conventional chemotherapy + TKI | − | Allo HSCT with RIC in CR1 (Haplo HSCT with RIC in the case of lacking an HLA-matched donor in CR1) |